(-0.57%) 5 078.25 points
(-0.29%) 38 567 points
(-0.97%) 17 494 points
(0.19%) $82.97
(-1.39%) $1.630
(0.05%) $2 339.60
(0.40%) $27.46
(0.27%) $918.30
(-0.22%) $0.932
(-0.34%) $10.95
(-0.45%) $0.799
(-0.25%) $92.09
@ $4.06
Issued: 12 Feb 2024 @ 16:00
Return: 0.12%
Live Chart Being Loaded With Signals
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...
Stats | |
---|---|
Today's Volume | 677 694 |
Average Volume | 849 600 |
Market Cap | 181.50M |
EPS | $0 ( 2024-03-14 ) |
Next earnings date | ( $0 ) 2024-05-11 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.03 |
ATR14 | $0.0670 (1.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Yi Kathy | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Yi Kathy | Sell | 99 634 | Stock Option (Right to Buy) |
2024-02-14 | Stein Steven H | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Orbimed Advisors Llc | Sell | 650 600 | Common Stock |
2024-02-14 | Hayden Donald J Jr | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
-12.36 |
Last 94 transactions |
Buy: 24 821 782 | Sell: 19 785 944 |
Volume Correlation
Theseus Pharmaceuticals, Correlation
10 Most Positive Correlations | |
---|---|
PXLW | 0.931 |
ADXN | 0.921 |
LIAN | 0.92 |
TNXP | 0.917 |
JFIN | 0.914 |
DSKE | 0.906 |
SPRB | 0.904 |
SRRK | 0.902 |
MEUSW | 0.897 |
LX | 0.895 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Theseus Pharmaceuticals, Correlation - Currency/Commodity
Theseus Pharmaceuticals, Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-22 507.00 (0.00 %) |
EPS: | $-0.310 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-158 709 (0.00 %) |
EPS: | $-0.340 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $-155 153 (0.00 %) |
EPS: | $-0.290 |
Financial Reports:
No articles found.
Theseus Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.238 | 1.200 | -7.94 | -9.52 | [0 - 0.3] |
returnOnEquityTTM | -0.245 | 1.500 | -3.83 | -5.75 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 29.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 29.29 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.70 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0156 | -1.500 | 9.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 88.35 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.567 | -1.134 | [0 - 20] |
debtEquityRatioTTM | 0.0163 | -1.500 | 9.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -13.58 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.984 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.19 | 1.000 | -0.423 | 0 | [1 - 100] |
returnOnEquityTTM | -0.245 | 2.50 | -2.46 | -5.75 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.378 | -1.134 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00632 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.553 |
Theseus Pharmaceuticals,
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators